Description: AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Home Page: www.abcellera.com
2215 Yukon Street
Vancouver,
BC
V5Y 0A1
Canada
Phone:
604 559 9005
Officers
| Name | Title |
|---|---|
| Dr. Carl L.G. Hansen Ph.D. | CEO, President & Chairperson |
| Mr. Andrew Booth M.B.A. | Chief Financial Officer |
| Dr. Veronique Lecault Ph.D. | COO & Director |
| Mr. Tryn T. Stimart Esq., J.D., M.Sc. | Chief Legal Officer, CCO, Compliance Officer, Corporate Secretary & Privacy Officer |
| Marcie Thiessen CPA, CGA | Senior Director of Finance & Accounting |
| Dr. Ester Falconer Ph.D. | Chief Technology Officer |
| Kathleen Reid B.A. | Head of Corporate Communications |
| Graham Craig M.Sc. | Director of Corporate Development |
| Mr. Murray McCutcheon Ph.D. | Senior Vice President of Partnering |
| Mr. Neil Aubuchon B.A., M.B.A. | Chief Commercial Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.7856 |
| Price-to-Sales TTM: | 24.2944 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 586 |